Can low-molecular-weight heparins improve outcome in patients with cancer?
- 30 June 2002
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 28 (3), 151-155
- https://doi.org/10.1016/s0305-7372(02)00040-3
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Variation in Relative Risk of Venous Thromboembolism in Different CancersThrombosis and Haemostasis, 2002
- Effects of a Low-Molecular-Weight Heparin on Thrombus Regression and Recurrent Thromboembolism in Patients with Deep-Vein ThrombosisNew England Journal of Medicine, 2001
- Prevention of Venous ThromboembolismSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2001
- Rates of Initial and Recurrent Thromboembolic Disease Among Patients with Malignancy Versus Those without Malignancy: Risk Analysis Using Medicare Claims DataMedicine, 1999
- Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinomaBritish Journal of Surgery, 1999
- Do Heparins Do More than Just Treat Thrombosis? The Influence of Heparins on Cancer SpreadThrombosis and Haemostasis, 1999
- Tissue factor in cancer angiogenesis and metastasisCurrent Opinion in Hematology, 1996
- Subcutaneous heparin treatment increases survival in small cell lung cancerCancer, 1994
- Prevalence of pulmonary embolism at necropsy in patients with cancer.Journal of Clinical Pathology, 1989
- Fatal Pulmonary Embolism in Cancer PatientsSouthern Medical Journal, 1980